Bank Of America Corp Terns Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 58,565 shares of TERN stock, worth $343,190. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,565

Previous 276,737 78.84%

Holding current value

$343,190

Previous $1.88 Million 74.1%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.49 - $10.8 $1.42 Million - $2.36 Million	-218,172 Reduced 78.84%	58,565 $488,000
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $1.08 Million - $1.95 Million	238,373 Added 621.35%	276,737 $1.88 Million
Q1 2024 May 15, 2024	SELL	$4.86 - $8.19 $99,396 - $167,501	-20,452 Reduced 34.77%	38,364 $251,000
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $51,055 - $103,929	15,150 Added 34.7%	58,816 $381,000
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $31,494 - $56,947	-4,285 Reduced 8.94%	43,666 $382,000
Q1 2023 May 12, 2023	BUY	$7.91 - $12.0 $364,935 - $553,632	46,136 Added 2541.93%	47,951 $567,000
Q4 2022 Feb 10, 2023	SELL	$4.62 - $10.18 $27,308 - $60,173	-5,911 Reduced 76.51%	1,815 $18,000
Q3 2022 Nov 14, 2022	SELL	$1.87 - $6.42 $19,414 - $66,652	-10,382 Reduced 57.33%	7,726 $46,000
Q2 2022 Aug 12, 2022	BUY	$1.5 - $3.0 $16,326 - $32,652	10,884 Added 150.66%	18,108 $44,000
Q1 2022 May 16, 2022	SELL	$2.83 - $6.7 $3,851 - $9,118	-1,361 Reduced 15.85%	7,224 $21,000
Q4 2021 Feb 08, 2022	BUY	$5.65 - $10.73 $19,509 - $37,050	3,453 Added 67.28%	8,585 $61,000
Q3 2021 Nov 15, 2021	BUY	$7.22 - $13.46 $1,133 - $2,113	157 Added 3.16%	5,132 $53,000
Q2 2021 Sep 13, 2021	BUY	$12.26 - $22.0 $60,993 - $109,450	4,975 New	4,975 $61,000

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Terns Pharmaceuticals, Inc. Transaction History